Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07774897

Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation

Certain classical formulas in traditional Chinese medicine and dietary prebiotics have demonstrated beneficial effects on various aspects of suboptimal health status in previous studies. This research aims to evaluate the effects of Bao Yuan Tang full-component extract combined with galactooligosaccharides on improving health-related outcomes in female registered nurse with suboptimal health status, including sleep disturbances, fatigue, endocrine dysregulation, and glucose and lipid metabolic abnormalities.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

About this study

The prevalence of suboptimal health status, including sleep disturbances and endocrine dysregulation, has been increasing in recent years, highlighting the significant public health and social implications of developing effective health-promoting interventions. Bao Yuan Tang, a classic traditional Chinese medicine formula with a long history of clinical application, has shown notable benefits in regulating various aspects of suboptimal health status, such as sleep disturbances. All herbs in the composition of Bao Yuan Tang, including Codonopsis Radix (Dangshen), Astragali Radix (Huangqi), Glycyrrhizae Radix et Rhizoma (Gancao), Cinnamomi Cortex (Rougui), Ziziphi Spinosae Semen (Suanzaoren), and charred jujube (Jiaozao), are listed in the catalogue of substances traditionally recognized as both food and Chinese medicinal materials issued by the National Health Commission of the People's Republic of China and the State Administration for Market Regulation. However, high-quality clinical studies evaluating its actual efficacy remain limited to date.

Galactooligosaccharides (GOS), forming a widely used class of dietary prebiotics, have also been shown potential benefits in improving conditions such as metabolic abnormalities, constipation, and obesity through modulation of the gut microbiota. Based on these findings, we developed a combination product containing Bao Yuan Tang full-component extract and GOS to investigate whether this combination could exert synergistic effects on improving suboptimal health status. This study is planned to evaluate the effects of a combination product, and Bao Yuan Tang extract or GOS alone, in young female registered nurse aged 25-45 years with night-shift exposure on suboptimal health status-related outcomes, including sleep disturbances, fatigue, endocrine dysregulation, and glucose and lipid metabolic abnormalities. Given the unique occupational characteristics of nursing staff, including irregular working hours and substantial work-related stress, this population considered suitable for inclusion in the present study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female registered nurses aged 25-45 years.
  • Participants must meet at least one of the following criteria, self-reported presence of at least one target symptom of the trial, including insomnia, daytime fatigue, or difficulty initiating sleep or Pittsburgh Sleep Quality Index (PSQI) score >7.
  • Engagement in shift work for at least one month before enrollment, with either ≥ 4 night shifts or ≥32 hours of night-shift work during the preceding month.

Exclusion criteria

  • Diagnosed with type 1 or type 2 diabetes mellitus and currently receiving pharmacological treatment.
  • Diagnosed with clinically thyroid dysfunction, including hyperthyroidism or hypothyroidism, and currently receiving pharmacological treatment.
  • Diagnosed with Cushing's syndrome, pituitary dysfunction, or other clearly defined endocrine disorders.
  • Diagnosed with polycystic ovary syndrome (PCOS) and currently receiving pharmacological treatment.
  • Use of medications that may affect study outcomes, including oral contraceptives, glucose-lowering agents, hormonal medications, hypnotics, lipid-regulating agents, or thyroid hormone preparations, within the past 3 months.
  • Pregnancy, lactation, or planned pregnancy during the study period.
  • Confirmed severe organic diseases, such as hepatic or renal insufficiency, cardiovascular disease, or malignancy.
  • Known allergy to any component of the investigational product.
  • Use of probiotics, prebiotics, or related traditional Chinese medicine preparations within the past 1 month.
  • Participation in another clinical trial within the past 3 months.
  • Planned engagement in vigorous exercise or a weight-management program during the study period.
  • A previous diagnosis of psychiatric disorders, such as anxiety or depression.
  • Any condition judged by the investigator to involve communication difficulties, poor compliance, or potential interference with adherence to the study protocol.

Treatment and study plan

Combination product (Bao Yuan Tang full-component extract 2.0g and galactooligosaccharides 2.0g)

Dietary Supplement

Participants will receive a combination product consisting of Bao Yuan Tang full-component extract (2.0g) and galactooligosaccharides (2.0g). The intervention will be administered twice daily, one sachet each time, for 3 weeks.

Bao Yuan Tang full-component extract 2.0g plus a placebo consisting of maltodextrin 2.0g

Dietary Supplement

Participants will receive Bao Yuan Tang full-component extract (2.0g) plus a placebo consisting of maltodextrin (2.0g). The intervention will be administered twice daily, one sachet each time, for 3 weeks.

Galactooligosaccharides 2.0g

Dietary Supplement

Participants will receive galactooligosaccharides (2.0g) combined with a maltodextrin placebo (2.0g). The intervention will be administered twice daily, one sachet each time, for 3 weeks.

maltodextrin placebo 4.0g

Other

Participants will receive maltodextrin placebo (4.0g), administered twice daily, one sachet each time, for 3 weeks.

Primary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI)

    Time frame: 1 month

    Sleep quality will be assessed the original standard PSQI. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. The data will be collected daily from baseline (Day 0) to the end (Day 30).

  2. Serum cortisol

    Time frame: Baseline (day 0), Day 10, and Day 21

    Blood samples will be collected at the day of enrollment and 10 and 21 days thereafter to assess changes in serum cortisol levels, the normal reference range is 140-630 nmol/L.

  3. Serum total cholesterol and triglyceride

    Time frame: Baseline (day 0), Day 10, and Day 21

    Blood samples will be collected at the day of enrollment and 10 and 21 days thereafter to measure serum total cholesterol and triglyceride levels, the normal reference levels are <5.2 mmol/L for total cholesterol and <1.7 mmol/L for triglycerides.

Secondary outcomes

  1. Changes in sleep efficiency

    Time frame: 1 month

    Sleep efficiency is calculated as total sleep time divided by time spent in bed × 100%, with ≥85% generally considered normal. The change from baseline (Day 0) to the end of the intervention (Day 30) will be evaluated.

  2. Sleep onset latency

    Time frame: 1 month

    Sleep onset latency is defined as the time from attempting to fall asleep to sleep onset, with >30 minutes generally indicating difficulty initiating sleep. The change from baseline (Day 0) to the end of the intervention (Day 30) will be evaluated.

  3. Multidimensional Fatigue Inventory (MFI-20)

    Time frame: 1 month

    Fatigue will be assessed using the original standard MFI-20. It includes five domains, each scored from 4 to 20, with higher scores indicating greater fatigue. The data will be collected daily from baseline (Day 0) to the end (Day 30).

  4. Fasting blood glucose

    Time frame: Baseline (day 0), Day 10, and Day 21

    Blood samples will be collected at the day of enrollment and 10 and 21 days thereafter to measure fasting blood glucose levels, The normal reference range is 3.9-6.1 mmol/L.

  5. Cluster of differentiation 4 positive/Cluster of differentiation 8 positive T-cell ratio

    Time frame: Baseline (Day 0), Day 10, and Day 21

    Peripheral blood samples will be collected on the day of enrollment and on Days 10 and 21 thereafter to measure the CD4+/CD8+ T-cell ratio by flow cytometry. The normal reference range is approximately 1.5 - 2.5.

  6. Serum estradiol (E2)

    Time frame: Baseline (Day 0), Day 10, and Day 21

    Blood samples will be collected on the day of enrollment and on Days 10 and 21 thereafter to measure serum estradiol (E2) levels. The reference ranges are 20 - 250 pg/mL in the follicular phase, 190 - 649 pg/mL during ovulation, and 21 - 350 pg/mL in the luteal phase.

  7. Gut microbiota analysis

    Time frame: Baseline (day 0), Day 10, and Day 21

    Stool samples will be collected on the day of enrollment and on Days 10 and 21 thereafter for gut microbiota analysis, Changes in α-diversity, β-diversity, and differential microbiota will be assessed.

Study contacts

Contact information is provided by the study sponsor or research team.

Liang Tian, M.D.

CONTACT

[email protected]

+8615293146623

Wenbo Meng, M.D., Ph.D.

CONTACT

[email protected]

+8613919177177

Sponsors and collaborators

Lead sponsor

Hepatopancreatobiliary Surgery Institute of Gansu Province

Other

Registry information

Official study title

Sleep-Promoting Effects of Bao Yuan Tang Whole-Component Extract Combined With Galactooligosaccharides: A Prospective, Multicenter, Triple-blind, Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 19, 2026
Registry last updated
Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.